Literature DB >> 22212580

Treatment of chronic hepatitis C--are interferons really necessary?

Peter Ferenci1.   

Abstract

Due to the side effect profile of pegylated interferons interferon treatment has become the holy grail of drug development for chronic hepatitis C. The precise role of interferon in treatment of hepatitis C is not fully understood, besides its antiviral effects interferon is an immune modulator. Nevertheless, recent proof of concept studies indicated, that cure of chronic hepatitis C can be achieved without interferon. Various compounds achieved this goal, like the polymerase inhibitor PSI 7977, the combination of NS5a inhibitor (daclatasvir) and a protease inhibitor (asunaprevir) and the cyclophillin antagonist alisporivir. Various other combinations are investigated currently. Providing that phase 3 studies will confirm these exciting data, direct acting antivirals or host targets will replace peginterferon/ribavirin combination therapy.
© 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22212580     DOI: 10.1111/j.1478-3231.2011.02705.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

Review 1.  The application and mechanism of action of ribavirin in therapy of hepatitis C.

Authors:  Emmanuel Thomas; Marc G Ghany; T Jake Liang
Journal:  Antivir Chem Chemother       Date:  2012-09-25

Review 2.  Treatment options for anti-HCV treatment-experienced patients.

Authors:  Peter Ferenci
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-04-26

3.  Sofosbuvir.

Authors:  Dennis J Cada; Jasen Cong; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-05

4.  Daclatasvir + asunaprevir: first global approval.

Authors:  Raewyn M Poole
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546

Review 5.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

6.  The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors.

Authors:  Sebastian M Lambert; David R Langley; James A Garnett; Richard Angell; Katy Hedgethorne; Nicholas A Meanwell; Steve J Matthews
Journal:  Protein Sci       Date:  2014-04-05       Impact factor: 6.725

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.